Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Keytruda Keeps Top Spot in Drug Sales Ranking in July: Encise
August 7, 2019
- Gearing Up for Japan Debut, Daiichi Sankyo Mounting Push for AML Med Vanflyta
August 6, 2019
- Daiichi Sankyo’s Pexidartinib Bags 1st FDA Nod for Rare Joint Tumor
August 6, 2019
- Fujifilm Completes Buyout of Biogen Manufacturing Unit, Tripling Its Bioreactor Capacity
August 6, 2019
- Ferring to Copromote Regenerative Medicine Product for Fertility Care Facilities
August 6, 2019
- Sosei, Takeda Seal Multi-Target Collaboration Deal
August 6, 2019
- AstraZeneca’s Japan Sales Surge 28% in H1 on Oncology Growth
August 6, 2019
- Rakuten Ups Its Stake in Rakuten Medical to 22.6%
August 5, 2019
- Gene Panel Testing Should Be Done “at an Early Stage”: Chugai Official
August 5, 2019
- Daiichi Sankyo Upping Pitches for Tarlige in May: Impact Track Survey
August 2, 2019
- Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO
August 2, 2019
- Kyowa Kirin Nets Double-Digit Growth in 1st Half, Keeps Full-Year Guidance for Nesp
August 2, 2019
- Ono’s Drug Sales Skid in Q1, but Opdivo Royalties Underpin Earnings
August 2, 2019
- Takeda Squeezes Projected Losses for FY2019 as Velcade Copy Lags
August 1, 2019
- Eisai Posts Flat Revenue in Q1, Lenvima Sales Double
August 1, 2019
- Daiichi Sankyo Logs Double-Digit Growth in Q1 as Olmetec Cliff Tails Off; Profit Zooms on AZ Deal, Asset Sale
August 1, 2019
- Medipal to Buy Back Shares from Takeda
August 1, 2019
- After 3rd PIII Try, Sumitomo Dainippon Finally Files Latuda for Japan Approval
August 1, 2019
- US FDA Accepts Sunovion’s Dasotraline Submission for Binge Eating Disorder
August 1, 2019
- Oita Univ. Spinout, Daiichi Sankyo Tie Up on Peptide Mimetics Research
July 31, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…